ALNY · Alnylam Pharmaceuticals

NASDAQ-100 #78 · Nasdaq

Risiko 7/10 · Biotech / RNAi pioneer · $288.41 ▲ 3.60%

Kennzahlen

• Price $288.41
• Market cap $38.5B
• P/E (ttm) 72.46
• Div yield none
• 52-wk range $262.21 – $495.55
• Index rank — / #78

Wichtigste Risiken

• Stock down ~40% from 52-week high (Shareholders) — EXTREME
• Pipeline trial read-out binary risk (Valuation) — HIGH
• High P/E requires sustained revenue acceleration (Valuation support) — HIGH
• Competitive pressure from emerging gene-editing platforms (Long-term moat) — MED

Fazit

Pioneer in RNA interference medicine with blockbuster amyloidosis franchise; revenue up 83% YoY but stock has halved from peak amid high growth expectations.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.